Evidence map›Paper›PMID 34889940›Full record

ArticleThe Journal of experimental medicine2022

P2RY8 variants in lupus patients uncover a role for the receptor in immunological tolerance.

Yuke He, Antonia E Gallman, Chengmei Xie, Qian Shen, Jianyang Ma, Finn D Wolfreys, Moriah Sandy, Todor Arsov, Xiaoqian Wu, Yuting Qin and 18 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Mapping malignant T-cell states and immune circuits in Sézary syndrome by single-cell analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
  3. Review
  4. Familial lupus associated with aJournal of human immunity · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Towards precision medicine for systemic lupus erythematosus and neuropsychiatric manifestations.Expert review of precision medicine and drug development · 2025
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 5 institutions in 4 countries.

Yuke He *Centre for Personalised Immunology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-6716-198X
Antonia E Gallman *Howard Hughes Medical Institute and Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA.ORCID 0000-0001-9107-8281
Chengmei XieCentre for Personalised Immunology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0001-7309-590X
Qian ShenCentre for Personalised Immunology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0003-1899-6937
Jianyang MaCentre for Personalised Immunology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-4203-700X
Finn D WolfreysHoward Hughes Medical Institute and Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA.ORCID 0000-0003-1057-633X
Moriah SandyHoward Hughes Medical Institute and Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-2658-4062
Todor ArsovCentre for Personalised Immunology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0003-4149-752X
Xiaoqian WuCentre for Personalised Immunology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-1432-6699
Yuting QinCentre for Personalised Immunology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0001-7506-2060
Pingjing ZhangCentre for Personalised Immunology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-6129-4685
Simon JiangCentre for Personalised Immunology, John Curtin School of Medical Research, Australian National University, Australian Capital Territory, Australia.ORCID 0000-0002-3973-5114
Maurice StanleyCentre for Personalised Immunology, John Curtin School of Medical Research, Australian National University, Australian Capital Territory, Australia.ORCID 0000-0002-1445-0892
Philip WuCentre for Personalised Immunology, John Curtin School of Medical Research, Australian National University, Australian Capital Territory, Australia.ORCID 0000-0002-8861-6226
Jingjing TanCentre for Personalised Immunology, John Curtin School of Medical Research, Australian National University, Australian Capital Territory, Australia.ORCID 0000-0001-6086-6517
Huihua DingShanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-7530-8953
Haiyan XueDepartment of Pediatrics, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0001-5682-3573
Wei ChenDepartment of Pediatrics, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-3436-3841
Jinping XuDepartment of Pediatrics, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0003-1155-559X
Lindsey A CriswellRussell/Engleman Rheumatology Research Center, Department of Medicine, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-0761-7543
Joanne NitithamRussell/Engleman Rheumatology Research Center, Department of Medicine, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-9972-1451
Marcin AdamskiCentre for Personalised Immunology, John Curtin School of Medical Research, Australian National University, Australian Capital Territory, Australia.ORCID 0000-0002-1703-6742
A Richard KitchingCentre for Personalised Immunology, Centre for Inflammatory Diseases, Monash University Department of Medicine, Clayton, Victoria, Australia.ORCID 0000-0002-2713-2391
Matthew C CookCentre for Personalised Immunology, John Curtin School of Medical Research, Australian National University, Australian Capital Territory, Australia.ORCID 0000-0002-3331-9363
Lanfang CaoDepartment of Pediatrics, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-0865-8320
Nan ShenCentre for Personalised Immunology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0002-5875-4417
Jason G Cyster *Howard Hughes Medical Institute and Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-4735-9745
Carola G Vinuesa *Centre for Personalised Immunology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0001-9799-0298
Shanghai Jiao Tong University · CNAustralian National University · AUHoward Hughes Medical Institute · USUniversity of California, San Francisco · USMonash University · AU

Funding

RESOURCE-BASED CENTER FOR THE ADVANCEMENT OF PRECISION MEDICINE IN RHEUMATOLOGYP30AR070155 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Mary C Nakamura · 2016 to 2026
$8.2M
Chemokines and Lymphoid Tissue Organization and FunctionR01AI045073 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CYSTER, JASON G · 1999 to 2023
$7.6M
Epidemiology of Lupus: Longitudinal Studies in Population-Based Cohorts - 2019U01DP006486 · DP · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DALL'ERA, MARIA · 2019 to 2021
$2.6M
Chemokines and Lymphoid Tissue Organization and FunctionR37AI045073 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jason G Cyster · 2024 to 2026
$1.7M
Dissecting the role of geranylgeranyl glutathione in the germinal center responseF30AI150061 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GALLMAN, ANTONIA · 2020 to 2022
$121k
CDC HHS U01DP006486Howard Hughes Medical InstituteNCCDPHP CDC HHS U01 DP006486NIAID NIH HHS F30 AI150061NIAID NIH HHS F30AI150061NIAID NIH HHS R01 AI045073NIAID NIH HHS R37 AI045073NIAMS NIH HHS P30 AR070155NIH HHS R01 AI045073
6 · The paper itself

Abstract

B cell self-tolerance is maintained through multiple checkpoints, including restraints on intracellular signaling and cell trafficking. P2RY8 is a receptor with established roles in germinal center (GC) B cell migration inhibition and growth regulation. Somatic P2RY8 variants are common in GC-derived B cell lymphomas. Here, we identify germline novel or rare P2RY8 missense variants in lupus kindreds or the related antiphospholipid syndrome, including a "de novo" variant in a child with severe nephritis. All variants decreased protein expression, F-actin abundance, and GPCR-RhoA signaling, and those with stronger effects increased AKT and ERK activity and cell migration. Remarkably, P2RY8 was reduced in B cell subsets from some SLE patients lacking P2RY8 gene variants. Low P2RY8 correlated with lupus nephritis and increased age-associated B cells and plasma cells. By contrast, P2RY8 overexpression in cells and mice restrained plasma cell development and reinforced negative selection of DNA-reactive developing B cells. These findings uncover a role of P2RY8 in immunological tolerance and lupus pathogenesis.

Indexed as

AnimalsAntiphospholipid SyndromeB-Lymphocyte SubsetsCell Line, TumorFemaleHEK293 CellsHumansImmune ToleranceLupus Erythematosus, SystemicLupus NephritisMaleMiceMice, Inbred C57BLMutation, MissensePedigreePlasma CellsP2RY8 protein, humanReceptors, Purinergic P2Y

Identifiers

PMID34889940
PMCPMC8669517
OpenAlexW4225808743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.